In control group of therapeutic scheme (non-treated animals with Krebs-2) CD4+ cell content slightly changed during tumor development from 17% (baseline) to 21% while CD8+ cell content significantly increased from 19% (baseline) to 29% by day 11 (Fig 4E). The gene discussed is CD8A; the disease is neoplasm.